1
|
Mohamed ZA, Pelletier S, Vintze-Geoffrion A, Lagacé-Nadon S, Olney HJ, Adam JP. Autologous Stem Cell Transplant for Treatment of Multiple Myeloma in a Patient with Concomitant Porphyria Cutanea Tarda. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 2021; 21:e264-e266. [PMID: 33390349 DOI: 10.1016/j.clml.2020.12.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/26/2020] [Revised: 11/27/2020] [Accepted: 12/04/2020] [Indexed: 10/22/2022]
Affiliation(s)
| | - Sarah Pelletier
- Faculty of Pharmacy, Université de Montréal, Montréal, QC, Canada
| | | | | | - Harold J Olney
- Division of Hematology-Oncology, Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada; Research Center of Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada.
| | - Jean-Philippe Adam
- Research Center of Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada; Department of Pharmacy, Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada
| |
Collapse
|
2
|
Ribeiro VST, Raboni SM, Suss PH, Cieslinski J, Kraft L, Dos Santos JS, Pereira L, Tuon FF. Detection and quantification of human immunodeficiency virus and hepatitis C virus in cadaveric tissue donors using different molecular tests. J Clin Virol 2019; 121:104203. [PMID: 31715525 DOI: 10.1016/j.jcv.2019.104203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2019] [Revised: 10/13/2019] [Accepted: 10/17/2019] [Indexed: 10/25/2022]
Abstract
BACKGROUND Tissues from cadaveric donors are used in several clinical circumstances, and the transmission of infectious diseases has been reported. Cadaveric donor (CD) blood sample analysis is challenging due to its poor quality. However, studies have demonstrated the usefulness of molecular based methods, and the lack of studies using available commercial molecular tests was reported. OBJECTIVE The aim of this study was to evaluate the performance, specificity, sensitivity, and accuracy of different commercial molecular tests for HIV and HCV detection and quantification in CD through spiked samples. STUDY DESIGN 20 CD and 20 blood donor samples were tested using 1,000 copies/mL and 1,000 IU/mL of lyophilized standards of HIV and HCV, respectively. Samples were analyzed by different molecular kits: XPERT HCV Viral Load and HIV-1 (Cepheid), COBAS® TaqMan® HIV-1 and COBAS® TaqMan® HCV Test, v2.0 (Roche), and artus® HI Virus-1 QS-RGQ and artus® HCV RG RT-PCR Kit (Qiagen). RESULTS HIV and HCV in CD were detected by RT-PCR-based quantitative kits. The tests performed by the Cepheid and the Roche kits showed the most accurate, sensitive and specific results, however, a wide variability between the assays and kits was observed. The Qiagen kits did not demonstrate satisfactory results. CONCLUSIONS CD evaluation showed great variability. The Cepheid and Roche kits were more sensitive for detecting HIV on CD and Cepheid was the most efficient kit for HCV quantification in CD. The Roche and Cepheid kits can be used to screen tissue donors for HIV and HCV.
Collapse
Affiliation(s)
- Victoria Stadler Tasca Ribeiro
- Laboratory of Emerging Infectious Diseases, School of Medicine, Pontifícia Universidade Católica do Paraná, Curitiba, PR, 80215-901, Brazil
| | - Sonia Mara Raboni
- Laboratory of Molecular Biology of Infectious Diseases, Universidade Federal do Paraná, Curitiba, PR, 80060-900, Brazil
| | - Paula Hansen Suss
- Laboratory of Emerging Infectious Diseases, School of Medicine, Pontifícia Universidade Católica do Paraná, Curitiba, PR, 80215-901, Brazil
| | - Juliette Cieslinski
- Laboratory of Emerging Infectious Diseases, School of Medicine, Pontifícia Universidade Católica do Paraná, Curitiba, PR, 80215-901, Brazil
| | - Letícia Kraft
- Laboratory of Emerging Infectious Diseases, School of Medicine, Pontifícia Universidade Católica do Paraná, Curitiba, PR, 80215-901, Brazil
| | - Jucélia Stadinicki Dos Santos
- Laboratory of Molecular Biology of Infectious Diseases, Universidade Federal do Paraná, Curitiba, PR, 80060-900, Brazil
| | - Luciane Pereira
- Laboratory of Molecular Biology of Infectious Diseases, Universidade Federal do Paraná, Curitiba, PR, 80060-900, Brazil
| | - Felipe Francisco Tuon
- Laboratory of Emerging Infectious Diseases, School of Medicine, Pontifícia Universidade Católica do Paraná, Curitiba, PR, 80215-901, Brazil.
| |
Collapse
|
3
|
Fishman JA, Greenwald MA, Grossi PA. Transmission of infection with human allografts: essential considerations in donor screening. Clin Infect Dis 2012; 55:720-7. [PMID: 22670038 DOI: 10.1093/cid/cis519] [Citation(s) in RCA: 112] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
Transmission of infection via transplantation of allografts including solid organs, eyes, and tissues are uncommon but potentially life-threatening events. Donor-derived infections have been documented following organ, tissue, and ocular transplants. Each year, more than 70 000 organs, 100 000 corneas, and 2 million human tissue allografts are implanted worldwide. Single donors may provide allografts for >100 organ and tissue recipients; each allograft carries some, largely unquantifiable, risk of disease transmission. Protocols for screening of organ or tissue donors for infectious risk are nonuniform, varying with the type of allograft, national standards, and availability of screening assays. In the absence of routine, active surveillance, coupled with the common failure to recognize or report transmission events, few data are available on the incidence of allograft-associated disease transmission. Research is needed to define the optimal screening assays and the transmissibility of infection with allografts. Approaches are reviewed that may contribute to safety in allograft transplantation.
Collapse
Affiliation(s)
- Jay A Fishman
- Transplant Infectious Disease Program, Infectious Disease Division, MGH Transplantation Center, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA.
| | | | | |
Collapse
|
4
|
Royer-Bégyn M, Teira P, Deybach JC, Mas E, Mazereeuw-Hautier J. [Porphyria cutanea tarda in a child undergoing bone marrow grafting]. Ann Dermatol Venereol 2010; 137:640-4. [PMID: 20932445 DOI: 10.1016/j.annder.2010.06.019] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2010] [Revised: 05/20/2010] [Accepted: 06/22/2010] [Indexed: 11/16/2022]
Abstract
BACKGROUND Porphyria cutanea tarda (PCT) is rare in childhood and association with bone marrow transplant has occasionally been reported. PATIENTS AND METHODS A 13-year-old boy was referred to our department for bullous lesions on sun-exposed areas. His past medical history revealed acute biphenotypic leukaemia with complete remission after allogeneic hematopoietic stem cell transplantation (unrelated donor). Complications of bone marrow transplant comprised anaemia (treated by blood transfusions), primary cytomegalovirus (CMV) infection, pulmonary aspergillosis and acute digestive graft-versus-host disease. The diagnosis of type I sporadic PCT was based on high levels of porphyria and normal erythrocytic uroporphyrinogen decarboxylase activity. The bullous lesions disappeared on bleeding, but the patient subsequently developed sclerodermiform lesions. DISCUSSION An association between PCT and bone marrow transplant has been reported previously in two independent cases, of which one involved a child. The causative role of bone marrow transplantation in the development of PCT could be related to several triggering factors: primary CMV infection, hepatotoxic drugs, blood transfusion and possible chronic hepatic graft-versus-host disease. CONCLUSION We report the second case in a child of type I PCT associated with bone marrow transplantation. This new case reinforces the hypothesis of a non-random relationship between the two conditions.
Collapse
Affiliation(s)
- M Royer-Bégyn
- Hôpital Larrey et hôpital des enfants, Toulouse, France.
| | | | | | | | | |
Collapse
|
5
|
Abstract
Trata-se de revisão sobre a porfiria cutânea tardia em que são abordados a fisiopatogenia, as características clínicas, as doenças associadas, os fatores desencadeantes, a bioquímica, a histopatologia, a microscopia eletrônica, a microscopia de imunofluorescência e o tratamento da doença.
Collapse
|
6
|
Sous le soleil du midi! Rev Med Interne 2000. [DOI: 10.1016/s0248-8663(00)89289-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
7
|
Abstract
Many patients with cutaneous porphyria have curable or controllable disease; untreated porphyria may prove fatal. The genetic defects and mechanisms underlying porphyria are steadily being delineated, treatments have become more appropriate and genetic counselling is now more accurate. A summary of the basic diagnostic features, management and recent advances in the cutaneous porphyrias is presented, based on a workshop held by the British Photodermatology Group.
Collapse
Affiliation(s)
- G M Murphy
- Photobiology Unit, Beaumont and Mater Misericordiae Hospitals, Dublin 7, Ireland.
| |
Collapse
|
8
|
Affiliation(s)
- G M Murphy
- Photobiology Unit, Beaumont and Mater Misericordiae Hospitals, Dublin, Ireland
| |
Collapse
|
9
|
McKenna DB, Browne M, O'Donnell R, Murphy GM. Porphyria cutanea tarda and hematologic malignancy--a report of 4 cases. PHOTODERMATOLOGY, PHOTOIMMUNOLOGY & PHOTOMEDICINE 1997; 13:143-6. [PMID: 9453083 DOI: 10.1111/j.1600-0781.1997.tb00218.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Porphyria cutanea tarda has been reported in association with a variety of myeloproliferative and lymphoproliferative disorders, suggesting a possible association between these conditions. We describe four patients presenting within a 12 month period with sporadic porphyria cutanea tarda shortly following the diagnosis of hematologic malignancy. A review of the literature and evidence supportive of a causal association are presented.
Collapse
Affiliation(s)
- D B McKenna
- Department of Dermatology, Beaumont Hospital, Dublin, Ireland
| | | | | | | |
Collapse
|
10
|
Remenyik E, Ujj G, Kiss A, Kószó F, Horkay I. Porphyria cutanea tarda and chronic lymphoid leukemia. PHOTODERMATOLOGY, PHOTOIMMUNOLOGY & PHOTOMEDICINE 1996; 12:180-2. [PMID: 9017795 DOI: 10.1111/j.1600-0781.1996.tb00196.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
A case of a familial porphyria cutanea tarda (PCT-II) is reported in which the clinically overt form of PCT was provoked by factors relating to chronic lymphoid leukemia (CLL). Typical lesions of PCT developed on a 55-year-old woman after several blood transfusions and chlorambucil treatment. Besides these provoking factors, cytomegalovirus (CMV) infection was diagnosed. Erythrocyte uroporphyrinogen decarboxylase activity was about 50% of normal in the patient and in her two children. This case supports the suggestion that development of PCT in patients with hematological disorders is more than coincidental but may in fact be provoked by exogenous factors relating to the treatment of leukemia.
Collapse
MESH Headings
- Anemia, Hemolytic, Autoimmune/etiology
- Antineoplastic Agents, Alkylating/administration & dosage
- Antineoplastic Agents, Alkylating/therapeutic use
- Blood Transfusion
- Chlorambucil/administration & dosage
- Chlorambucil/therapeutic use
- Cytomegalovirus Infections/complications
- Erythrocytes/enzymology
- Female
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell/blood
- Leukemia, Lymphocytic, Chronic, B-Cell/complications
- Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy
- Leukemia, Lymphocytic, Chronic, B-Cell/therapy
- Middle Aged
- Porphyria Cutanea Tarda/blood
- Porphyria Cutanea Tarda/etiology
- Porphyria Cutanea Tarda/genetics
- Uroporphyrinogen Decarboxylase/metabolism
Collapse
Affiliation(s)
- E Remenyik
- Department of Dermatology, University Medical School, Debrecen, Hungary
| | | | | | | | | |
Collapse
|
11
|
Batlle AM. Porphyrins, porphyrias, cancer and photodynamic therapy--a model for carcinogenesis. JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY. B, BIOLOGY 1993; 20:5-22. [PMID: 8229469 DOI: 10.1016/1011-1344(93)80127-u] [Citation(s) in RCA: 142] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Porphyrins are the only and most powerful photosensitizers synthesized internally. To understand better the involvement of porphyrins in photosensitization reactions, the heme biosynthetic pathway is first described, as well as the main features of its regulation in both erythroid and hepatic cells. Most disorders of porphyrin metabolism, known as porphyrias, are characterized by porphyrin accumulation. A full discussion of these diseases, their classification and relevant biochemical and clinical signs are presented. Abnormalities in heme biosynthesis in disorders other than porphyrias, such as iron-deficient and sideroblastic anemias, lead poisoning, hereditary tyrosinemia, chronic renal disease and alcoholism, are briefly considered. A complete survey of the experimental research on the biosynthesis of porphyrins in tumors and of the important association between cancer and porphyrias is dealt with. The link to photodynamic therapy (PDT) emerges naturally and this is treated from the point of view of using porphyrins endogenously formed by the tumors for their localization and PDT. Finally, considering the nature of the alterations occurring in heme metabolism in tumors, and porphyrias and their ubiquity, a model is discussed where the abnormality of heme synthesis is involved in the initiating lesion of carcinogenesis. The model strongly predicts that the incidence of cancer will be high in cells with abnormal heme metabolism, suggesting that porphyric patients may be at greater risk of the development of cancer.
Collapse
Affiliation(s)
- A M Batlle
- Centro de Investigaciones sobre Porfirinas y Porfirias-CIPYP, CONICET-FCEN, UBA, Buenos Aires, Argentina
| |
Collapse
|
12
|
Borbolla JR, Cuesta B, Rifón J, Sarrá J, Prosper F, Rocha E. Porphyria cutanea tarda associated with acute non-lymphoblastic leukemia. Am J Hematol 1992; 40:241-2. [PMID: 1609784 DOI: 10.1002/ajh.2830400321] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
|